Replicase-based DNA vaccines for allergy treatment

Area of Science:

• Vaccinology
• Molecular Biology
• Immunology

Background:

• Conventional DNA and RNA vaccines face challenges with efficiency and stability.
• Replicase-based vaccines, derived from alphaviruses, were developed to address these limitations.
• These novel vaccine vectors offer enhanced performance at ultra-low doses.

Purpose of the Study:

• To describe the construction of a replicon-based DNA vaccine vector using commercially available plasmids.
• To present protocols for monitoring cellular immune responses after replicase-based immunization.
• To evaluate the induction of both cellular and humoral immune responses.

Main Methods:

• Construction of a replicon-based DNA vaccine vector from commercial plasmids.
• Measurement of allergen-specific splenocyte proliferation.
• Enzyme-linked immunosorbent spot (ELISPOT) assay.
• Fluorescence-activated cell sorting (FACS)-based cytokine secretion assay for T-helper subsets.
• Cytokine fluorescent bead immunoassay.

Main Results:

• Replicase-based vectors elicit significant cellular and humoral immune responses.
• These vectors demonstrate effective self-removal via apoptosis of transfected cells.
• Protocols for monitoring cellular immunity, including T-helper subset analysis, were successfully applied.

Conclusions:

• Replicase-based DNA vaccine vectors provide a promising alternative to conventional vaccines.
• They offer improved immunogenicity and a built-in safety mechanism (self-removal).
• Established methods effectively assess the immune responses elicited by these novel vectors.